Dr. Levis Discusses Quizartinib In Aml

Dr. Levis Discusses Quizartinib in AML

Dr. Levis Discusses the Ideal Use of Quizartinib in FLT3-ITD AML

Dr. Levis on Quizartinib in AML Patients Without the FLT3-ITD Mutation

Targeted Oncology

Dr. Levis on the Background and Future of Quizartinib for AML

Targeted Oncology

Dr. Levis on a Phase II Trial Examining Quizartinib in AML

Targeted Oncology

Dr. Levis on the Ideal Way to Use Quizartinib to Treat AML

Targeted Oncology

Dr. Levis on the Challenges of Treating FLT3-ITD AML

Targeted Oncology

Dr. Levis on Gilteritinib in Relapsed/Refractory FLT3-Mutated AML

Dr. Levis on the Challenges of Treating FLT3-ITD AML

Potential approval of quizartinib in AML & its place in the AML treatment regimen

VJHemOnc – Video Journal of Hematology & HemOnc

Quizartinib in AML

Mark Levis, MD, PhD, discusses what we've learned about gilteritinib in FLT3 mutated AML patients

QuANTUM-First: the benefit of quizartinib based on pre-transplant MRD status

VJHemOnc – Video Journal of Hematology & HemOnc

Quizartinib provides clinical benefit in R/R FLT3-ITD AML

VJHemOnc – Video Journal of Hematology & HemOnc

Final Thoughts on Emerging Therapies for AML

Inhibitors of FLT3 flying into 2019: what to expect this year

VJHemOnc – Video Journal of Hematology & HemOnc

Tangible benefit for FLT3-ITD R/R AML on quizartinib

VJHemOnc – Video Journal of Hematology & HemOnc

Quizartinib for frontline FLT3-ITD+ AML: updated results from the QuANTUM-First trial

VJHemOnc – Video Journal of Hematology & HemOnc

Mark Levis, MD, on why the FLT3 target is important in AML

ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

American Society of Hematology